Tenax Therapeutics, Inc.
TENX
$14.61
$0.775.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.71M | 20.51M | 15.53M | 11.21M | 6.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.39M | 47.23M | 35.04M | 26.92M | 19.49M |
| Operating Income | -56.39M | -47.23M | -35.04M | -26.92M | -19.49M |
| Income Before Tax | -52.60M | -43.33M | -31.48M | -24.21M | -17.60M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.60 | -43.33 | -31.48 | -24.21 | -17.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.60M | -43.33M | -31.48M | -24.21M | -17.60M |
| EBIT | -56.39M | -47.23M | -35.04M | -26.92M | -19.49M |
| EBITDA | -- | -7.29M | -11.91M | -15.58M | -19.49M |
| EPS Basic | -1.34 | -1.13 | -0.92 | -2.47 | -5.31 |
| Normalized Basic EPS | -0.84 | -0.71 | -0.58 | -1.55 | -3.32 |
| EPS Diluted | -1.34 | -1.13 | -0.92 | -2.47 | -5.31 |
| Normalized Diluted EPS | -0.84 | -0.71 | -0.58 | -1.55 | -3.32 |
| Average Basic Shares Outstanding | 156.82M | 151.19M | 132.61M | 95.00M | 59.63M |
| Average Diluted Shares Outstanding | 156.82M | 151.19M | 132.61M | 95.00M | 59.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |